Advertisement
Screener

Neuronetics, Inc. (STIM) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

2.6 / 5 stars · 33/64 Roast Me

Neuronetics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

Neuronetics, Inc. (STIM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.09 per share for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-07.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2023-03-07

  • Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $1.52, a 82.98% decline year-over-year.
  • Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $8.93.
  • Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $1.09, a 85.83% decline from fiscal 2019.
  • Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $7.69, a 52.88% increase from fiscal 2018.
  • Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $5.03, a 246.90% increase from fiscal 2017.
  • Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2017 was $1.45, a 25.00% increase from fiscal 2016.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month
2020-12-31$1.09
10-K · filed 2023-03-07
2020-09-30$1.02
10-Q · filed 2020-11-02
2020-06-30$1.52
10-Q · filed 2020-08-04
2020-03-31$1.52
10-Q · filed 2020-05-05
2019-12-31$7.69
10-K · filed 2022-03-08
2019-09-30$7.99
10-Q · filed 2019-11-05
2019-06-30$8.70
10-Q · filed 2019-08-06
2019-03-31$8.93
10-Q · filed 2019-05-07
2018-12-31$5.03
10-K · filed 2021-03-02
2018-09-30$4.38
10-Q · filed 2018-11-06
2018-06-30$3.64
10-Q · filed 2018-08-14
2017-12-31$1.45
10-K · filed 2020-03-03
2016-12-31$1.16
10-K · filed 2019-03-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Profound Medical Corp. (PROF)$0.206B-7.37
PRO DEX INC (PDEX)United States$0.234B13.64
UTAH MEDICAL PRODUCTS INC (UTMD)United States$0.238B20.93
InfuSystem Holdings, Inc (INFU)United States$0.253B22.52
Lucid Diagnostics Inc. (LUCD)United States$0.170B
Anika Therapeutics, Inc. (ANIK)United States$0.272B-51.71
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
Cytosorbents Corp (CTSO)United States$0.274B-1.29
KORU Medical Systems, Inc. (KRMD)United States$0.151B-106.78
TriSalus Life Sciences, Inc. (TLSI)United States$0.283B-9.92